Best mode for treating hard cataracts

Article

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

Liu Yizhi, MD, PhD of the Zhongshan Ophthalmic Center at Sun Yat-sen University, Guangzhou, China and colleagues assessed the effects on "hard" cataracts of the "multiburst" and "shortburst" settings of the Sovereign phaco machine (AMO) in comparison to the settings on the Whitestar technology platform (AMO).

The differences between the three groups were statistically significant. The ultrasonic power was highest for the Whitestar, followed by Sovereign's shortpulse and then the multiburst setting. The multiburst setting had the highest ultrasonic power release time, effective phaco time and rate of endothelial cell loss; the group displaying the lowest levels of these variables was the Whitestar group. In the multiburst group, there was also one case of wound burn and three eyes displaying abnormal fluctuations in the anterior chamber depth.

Based on these data, the research team concluded that, while Sovereign's multiburst mode was an unreliable method of performing this type of surgery, Whitestar technology had the best results of the study and offers an acceptable alternative.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.